Fiche publication
Date publication
février 2018
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MERROUCHE Yacine
,
Dr VIGNOT Stéphane
Tous les auteurs :
Jaillais A, Herber-Mayne A, D'Alteroche L, Landau A, Merrouche Y, Vignot S
Lien Pubmed
Résumé
Patients with chronic hepatitis B infection are at risk of viral reactivation when treated by immuno- or chemotherapy, with potentially serious or even fatal consequences. This article proposes an overview on screening strategies and antiviral treatment recommendations for oncology patients. We have learned in hematology that reactivations are commun with rituximab and prophylactic treatment is recommanded for any patient who has been in contact with the virus. The risk appears to be lower with cytotoxics but has been far less studied. The recommandations are not formally consensual and upcoming studies will help to establish clearer practice guidelines.
Mots clés
Allografts, Anthracyclines, adverse effects, Antineoplastic Agents, adverse effects, Antiviral Agents, adverse effects, Hematopoietic Stem Cell Transplantation, Hepatitis B Antigens, blood, Hepatitis B virus, drug effects, Hepatitis B, Chronic, diagnosis, Humans, Neoplasms, drug therapy, Rituximab, adverse effects, Virus Activation
Référence
Bull Cancer. 2018 Feb;105(2):162-170
